Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Agomelatine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A known ✓ | P48039 | 18/20 | 1.00 |
| ▸ | MTNR1B known ✓ | P49286 | 9/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | NQO2 | P16083 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Agomelatine SCHEMBL27844916 | 1.00 | MTNR1A (1.00) | MTNR1AMTNR1BHTR2CHTR2BNQO2 | |
| Agomelatine SCHEMBL1158495 | 1.00 | MTNR1A (1.00) | MTNR1AMTNR1BHTR2CHTR2BNQO2 | |
| Agomelatine SCHEMBL29930659 | 1.00 | MTNR1A (1.00) | MTNR1AMTNR1BHTR2CHTR2BNQO2 | |
| Agomelatine SCHEMBL27855409 | 0.99 | MTNR1A (0.97) | MTNR1AMTNR1BHTR2CHTR2BNQO2 | |
| Agomelatine SCHEMBL28522576 | 0.99 | MTNR1A (0.97) | MTNR1AMTNR1BHTR2CHTR2BNQO2 | |
| Agomelatine SCHEMBL27785485 | 0.99 | MTNR1A (0.97) | MTNR1AMTNR1BHTR2CHTR2BNQO2 | |
| Agomelatine SCHEMBL1289524 | 0.99 | MTNR1A (0.97) | MTNR1AMTNR1BHTR2CHTR2BNQO2 | |
| Agomelatine SCHEMBL28116100 | 0.99 | MTNR1A (0.97) | MTNR1AMTNR1BHTR2CHTR2BNQO2 | |
| Agomelatine SCHEMBL2454293 | 0.97 | MTNR1A (0.95) | MTNR1AMTNR1BHTR2CHTR2BNQO2 | |
| Agomelatine SCHEMBL2371196 | 0.97 | MTNR1A (0.95) | MTNR1AMTNR1BHTR2CHTR2BNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7074 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075413-A | Amorphous solid dispersion of tigorason, tablet core containing tigorason, tigorason tablet and preparation process of amorphous solid dispersion of tigorason | — | 2026-05-26 | — | — | CN | claimed |
| CN-117964510-B | Agomela Process for the preparation of a statin | 浙江东亚药业股份有限公司 | 2026-05-19 | — | — | CN | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12594028-B1 | EEG montage for facilitating selection of drug treatment in patients suffering from psychiatric disorders | ALTO NEUROSCIENCE, INC. (US) | 2026-04-07 | — | — | US | claimed |
| US-20260090584-A1 | SYSTEMS AND METHODS FOR ESTIMATING AEROSOLIZATION EMISSION | SCIENTIFIC HORIZONS CONSULTING LLC (US) | 2026-04-02 | — | — | US | claimed |
| EP-4712996-A1 | HIP/PAP PROTEIN OR A DERIVATIVE THEREOF FOR TREATING A COGNITIVE DISORDER ASSOCIATED WITH ANXIETY DISORDER | THE HEALTHY AGING COMPANY (FR) | 2026-03-25 | — | — | EP | claimed |
| CN-121570429-A | Amorphous agomelatine tablet and preparation method thereof | 宁波美诺华天康药业有限公司 | 2026-02-27 | — | — | CN | claimed |
| US-12558358-B2 | N-(furan-2-ylmethyl)-7H-purin-6-amine for treatment of circadian rhythm diseases, disorders and dysfunctions | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2026-02-24 | — | — | US | claimed |
| US-12544385-B2 | Combination drug therapies for CNS disorders | JAVED MOHAMMAD (US) | 2026-02-10 | — | — | US | claimed |
| US-20050137247-A1 | Methods and compositions for treatment of hypertension | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-06-23 | — | — | US | claimed |
| US-20050131071-A1 | Orodispersible pharmaceutical composition of agomelatine | LES LABORATOIRES SERVIER (FR) | 2005-06-16 | — | — | US | claimed |
| WO-2005053796-A1 | USE OF D4 AND 5-HT2A ANTAGONISTS, INVERSE AGONISTS OR PARTIAL AGONISTS | B & B BEHEER NV (BE) | 2005-06-16 | — | — | WO | claimed |
| EP-1541197-A1 | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists | B&B Beheer NV (BE) | 2005-06-15 | — | — | EP | claimed |
| CN-1622804-A | Orodispersible pharmaceutical composition of agomelatine | SERVIER LAB (FR) | 2005-06-01 | — | — | CN | claimed |
| WO-2005002562-A1 | THE COMBINATION OF A SEROTONIN REUPTAKE INHIBITORS AND AGOMELATINE | H. LUNDBECK A/S (DK) | 2005-01-13 | — | — | WO | claimed |
| US-6319520-B1 | COPOLYMERS OF AMMONIUM METHACRYLATE THAT CONSIST OF FULLY POLYMERIZED COPOLYMERS OF ACRYLIC ACID AND METHACRYLIC ACID ESTER HAVING QUATERNARY AMMONIUM GROUPS | ADIR ET COMPAGNIE (FR) | 2001-11-20 | — | — | US | claimed |
| EP-1064935-A1 | Solid thermoformable controlled-release pharmaceutical composition | ADIR ET COMPAGNIE (FR) | 2001-01-03 | — | — | EP | claimed |
| EP-0447285-B1 | NAPHTHALENE DERIVATIVES, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ADIR ET COMPAGNIE (FR) | 1993-05-12 | — | — | EP | claimed |
| EP-0447285-A1 | Naphthalene derivatives, procedure for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1991-09-18 | — | — | EP | claimed |